The percentage of NK cells out of tumor infiltrating lymphocytes (CD45+) was increased in tumors of mice treated with anti-CTLA-4 and BEMPEG as compared to all other groups (p<0.01, Figure 3A). This evidence concerns the gene CTLA4 and neoplasm.